Literature DB >> 19717293

Natural killer cell allorecognition of missing self in allogeneic hematopoietic transplantation: a tool for immunotherapy of leukemia.

Andrea Velardi1, Loredana Ruggeri, Antonella Mancusi, Franco Aversa, Frank T Christiansen.   

Abstract

Donor-versus-recipient natural killer (NK) cell alloreactivity has been established as a key therapeutic element in HLA haplotype mismatched hematopoietic transplants in adult AML and pediatric ALL and as a possible beneficial effector in cord blood transplant for AML. It is effected by functional NK cells which express inhibitory killer cell immunoglobulin-like receptor(s) (KIR) for self-class I ligand(s), sense missing expression of donor KIR ligand(s) in the recipient and mediate alloreactions. At present NK cell allotherapy for leukemia is deployed through stem cell transplantation (and ensuing NK cell reconstitution) across KIR ligand mismatches. Studies have been performed to infuse NK cells for immunotherapy outside the fields of transplantation and/or harness the function of endogenous NK cells in patients with hematological malignancies.

Entities:  

Mesh:

Year:  2009        PMID: 19717293     DOI: 10.1016/j.coi.2009.07.015

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  50 in total

1.  Differential impact of inhibitory and activating Killer Ig-Like Receptors (KIR) on high-risk patients with myeloid and lymphoid malignancies undergoing reduced intensity transplantation from haploidentical related donors.

Authors:  D-F Chen; V K Prasad; G Broadwater; N L Reinsmoen; A DeOliveira; A Clark; K M Sullivan; J P Chute; M E Horwitz; C Gasparetto; G D Long; Y Yang; N J Chao; D A Rizzieri
Journal:  Bone Marrow Transplant       Date:  2011-12-05       Impact factor: 5.483

2.  Mutation at positively selected positions in the binding site for HLA-C shows that KIR2DL1 is a more refined but less adaptable NK cell receptor than KIR2DL3.

Authors:  Hugo G Hilton; Luca Vago; Anastazia M Older Aguilar; Achim K Moesta; Thorsten Graef; Laurent Abi-Rached; Paul J Norman; Lisbeth A Guethlein; Katharina Fleischhauer; Peter Parham
Journal:  J Immunol       Date:  2012-07-06       Impact factor: 5.422

Review 3.  T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effect.

Authors:  C Russell Cruz; Catherine M Bollard
Journal:  Haematologica       Date:  2015-06       Impact factor: 9.941

4.  T-cell depletion: from positive selection to negative depletion in adult patients.

Authors:  F Aversa
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

5.  Next generation HLA-haploidentical HSCT.

Authors:  M F Martelli; M D Ianni; L Ruggeri; F Falzetti; A Carotti; Y Reisner; A Velardi
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

6.  HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8⁺ T lymphocytes.

Authors:  Marloes Gooden; Margit Lampen; Ekaterina S Jordanova; Ninke Leffers; J Baptist Trimbos; Sjoerd H van der Burg; Hans Nijman; Thorbald van Hall
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-13       Impact factor: 11.205

Review 7.  Immunotherapy prospects for acute myeloid leukaemia.

Authors:  A J Barrett; K Le Blanc
Journal:  Clin Exp Immunol       Date:  2010-05-31       Impact factor: 4.330

8.  In vivo proof of concept of adoptive immunotherapy for hepatocellular carcinoma using allogeneic suicide gene-modified killer cells.

Authors:  Céline Leboeuf; Laurent Mailly; Tao Wu; Gaetan Bour; Sarah Durand; Nicolas Brignon; Christophe Ferrand; Christophe Borg; Pierre Tiberghien; Robert Thimme; Patrick Pessaux; Jacques Marescaux; Thomas F Baumert; Eric Robinet
Journal:  Mol Ther       Date:  2013-12-06       Impact factor: 11.454

Review 9.  Human Cytokine-Induced Memory-Like Natural Killer Cells.

Authors:  Melissa M Berrien-Elliott; Julia A Wagner; Todd A Fehniger
Journal:  J Innate Immun       Date:  2015-04-30       Impact factor: 7.349

10.  Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells.

Authors:  Jeffrey W Leong; Julie M Chase; Rizwan Romee; Stephanie E Schneider; Ryan P Sullivan; Megan A Cooper; Todd A Fehniger
Journal:  Biol Blood Marrow Transplant       Date:  2014-01-13       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.